Barcelona

• A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended
  2024-513885-20-00 4 2022-12-05 Insomnia Disorder
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi … Ended
  2022-500652-37-00 4 2022-12-01 Advanced melanoma refractory to prior checkpoint inhibitor therapy
• A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended
  2022-500445-24-00 5 2022-11-30 Moderately to Severely Active Systemic Lupus Erythematosus
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• Phase I study of MGY825 in patients with lung cancer Ended
  2023-504350-36-00 1 2022-11-25 Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Dru … Ended
  2024-513708-33-00 1 2022-11-23 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy Ended
  2023-509876-40-00 4 2022-11-22 Multiple System Atrophy
• Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors Ended
  2024-512710-17-00 1 2022-11-22 Advanced solid tumors
• Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo … Ended
  2024-513262-19-00 5 2022-11-21 Thrombotic Thrombocytopenic Purpura
• Safety and Immunogenicity of V116 in Adults 50 Years of Age or Older Ended
  2022-503144-40-00 5 2022-11-17 Pneumococcal disease
• A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended
  2023-505904-41-00 5 2022-11-17 Hereditary Angioedema Type I or II
• Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended
  2024-511281-36-00 5 2022-11-17 Refractory Invasive Pulmonary Aspergillosis
• Study to evaluate the impact of VCN-01 on the overall survival of patients with advanced pancreatic cancer treated with standard therapy. Ended
  2024-511290-30-00 4 2022-11-15 Metastatic Pancreatic Cancer
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment … Ended
  2022-500774-34-00 3 2022-11-08 Urticaria
• A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment co … Ended
  2022-500775-31-00 3 2022-11-08 Allergic rhinitis
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S … Ended
  2024-511610-20-00 4 2022-11-08 Alzheimer's Disease
• Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors Ended
  2024-514357-29-00 1 2022-11-04 Advanced solid tumors
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy and in Com … Ended
  2022-502419-12-00 7 2022-11-02 Malignant Solid Tumors
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended
  2023-508404-37-00 3 2022-10-26 Non-muscle Invasive Bladder Cancer

Showing 2,953–2,976 of 3,391 trials